Table 1. Summary statistics of studies analyzed.
| P. falciparum | P. vivax | |
|---|---|---|
| Number of studies | 153 | 54 |
| Number of data points1 | 275 | 115 |
| Number of surveyed individuals | 105609 | 39671 |
| Number of genotyped individuals | 33526 | 13325 |
| Method for diagnosis of infection2 | ||
| Microscopy/RDT | 180 (66.4%) | 61 (51.7%) |
| PCR | 91 (33.6%) | 57 (48.3%) |
| Number of genotyping markers2 | ||
| 1 marker | 133 (49.1%) | 11 (9.4%) |
| >1 marker | 138 (50.9%) | 106 (90.6%) |
| Method for genotyping2 | ||
| Size polymorphic - gel | 214 (79.0%) | 18 (15.4%) |
| Size polymorphic - CE | 51 (18.8%) | 89 (76.1%) |
| SNP panel | 1 (0.4%) | 1 (0.9%) |
| Amplicon sequencing | 5 (1.8%) | 4 (3.4%) |
| WGS | 0 (0.0%) | 5 (4.3%) |
| Clinical symptoms2 | ||
| Asymptomatic | 120 (44.3%) | 26 (22.0%) |
| Clinical | 151 (55.7%) | 92 (78.0%) |
| Age range2 | ||
| All ages | 162 (59.8%) | 102 (86.4%) |
| <15 years | 92 (34.0%) | 7 (5.9%) |
| >15 years | 17 (6.3%) | 9 (7.6%) |
| Geographic region2 | ||
| Africa | 214 (79.0%) | 11 (9.3%) |
| Asia-Pacific | 51 (18.8%) | 84 (71.2%) |
| Latin America | 6 (2.2%) | 23 (19.5%) |
| Mean proportion of polyclonal infections [range] | 57.0% [0–98.9] | 42.8% [0–100] |
| Mean MOI [range] | 2.26 [1–6.1] | 1.59 [1–3.8] |
Table 1: Characteristics of studies analyzed.
1 Multiple data points were retrieved from a study if data was reported separately for different locations, age groups, time points, or separately for clinical and asymptomatic individuals.
2 For each factor, the number and percentage of data points is given.